Septerna (SEPN) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Septerna (SEPN) has outperformed Zymeworks (ZYME) over the past year, gaining 51.1% versus a gain of 8.8%. Septerna is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size. Zymeworks converts more of its revenue into profit, with a net margin of -76.6% versus -106.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | ZYME |
|---|---|---|
| Share price | $38.61 | $26.14 |
| Market cap | $1.84B | $1.81B |
| 1-day change | -1.51% | -2.68% |
| YTD return | +38.49% | -0.72% |
| 1-year return | +51.06% | +8.83% |
| 5-year return | — | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-1.30 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | $105.97M |
| Revenue growth (YoY) | +4174.51% | +38.87% |
| Net income (latest FY) | $-48.88M | $-81.13M |
| Operating margin | -148.63% | -87.34% |
| Net margin | -106.37% | -76.56% |
| 52-week high | $53.34 | $31.97 |
| 52-week low | $22.78 | $21.52 |
| Distance from 52-week high | -27.62% | -18.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.38% | +65.61% |
| Average volume | 383.96K | 1.09M |
| Shares outstanding | 47.55M | 68.70M |
| Employees | 134 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed ZYME by 42.2 percentage points over the past year.
- Zymeworks is more profitable, keeping -76.6 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +38.87%).
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
SEPN vs ZYME FAQ
Which is bigger, Septerna or Zymeworks?
Septerna (SEPN) is larger, with a market capitalization of $1.84B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, SEPN or ZYME?
SEPN returned +51.06% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.